View in EDS

The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.

Saved in:
Bibliographic Details
Title: The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
Authors: Peper-Gabriel JK; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany., Pavlidou M; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany., Pattarini L; Institut de Recherches Servier, Center for Therapeutic Innovation Oncology, Croissy-sur-Seine, France., Morales-Kastresana A; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany., Jaquin TJ; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany., Gallou C; Institut de Recherches Servier, Center for Therapeutic Innovation Oncology, Croissy-sur-Seine, France., Hansbauer EM; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany., Richter M; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany., Lelievre H; Institut de Recherches Internationales Servier Oncology R&D Unit, Suresnes, France., Scholer-Dahirel A; Institut de Recherches Internationales Servier Oncology R&D Unit, Suresnes, France., Bossenmaier B; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany., Sancerne C; Institut de Recherches Servier, Center for Therapeutic Innovation Oncology, Croissy-sur-Seine, France., Riviere M; Institut de Recherches Servier, Center for Therapeutic Innovation Oncology, Croissy-sur-Seine, France., Grandclaudon M; Institut de Recherches Servier, Center for Therapeutic Innovation Oncology, Croissy-sur-Seine, France., Zettl M; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany., Bel Aiba RS; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany., Rothe C; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany., Blanc V; Institut de Recherches Servier, Center for Therapeutic Innovation Oncology, Croissy-sur-Seine, France., Olwill SA; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Aug 02; Vol. 28 (15), pp. 3387-3399.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-21-2762